$LLY$NVO
Lilly’s Oral GLP-1 Foundayo showed cardiovascular safety while also lowering blood sugar and body weight in the Phase 3 ACHIEVE-4 trial.
The study included 2,749 adults with type 2 diabetes and overweight or obesity who were at increased cardiovascular risk.
$NVO is cutting the price of Wegovy in Sweden by 20% from today, October 1.
The reduction will save patients around SEK 500 or more per month depending on the dose. Novo says the decision reflects the fact that people with obesity in Sweden currently have to pay for Wegovy out
$NVO ’s U.S.-listed ADR closed at $37.91, equivalent to DKK 250.39, below the Copenhagen close of DKK 253.20.
The ADR later traded around $37.93 in after-hours (≈ DKK 250.52), suggesting a slightly negative open in Copenhagen today.
Jyske Bank maintains a DKK 330 price target on $NVO with a Hold rating
The bank sees substantial long-term potential in Novo’s pipeline, with more than five potential multi-blockbusters representing over DKK 150 billion in risk-adjusted sales potential by 2035.
Jyske Bank
The Financial Times argues that $NVO ’s $2.6 billion licensing deal with China’s Hengrui Pharma says as much about Hengrui’s growing strength as it does about Novo.
Hengrui has transformed from a generics manufacturer into a major R&D-focused pharmaceutical company. R&D spending
